How The Evolus (EOLS) Story Is Shifting As Analysts Reset Growth And Valuation Assumptions [Yahoo! Finance]
Evolus, Inc. (EOLS)
Last evolus, inc. earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
us.evolis.com/investor-relations
Company Research
Source: Yahoo! Finance
Evolus is back in focus after analysts revisited their price target framework, keeping the fair value unchanged at $14.67 per share. Some see the maintained target as confirmation that the core thesis is intact, while others read the previous $4 cut as a sign that expectations around long term revenue may have been reset. As you read on, you will see how to interpret this evolving analyst narrative and what to watch if you are tracking Evolus from here. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Evolus. What Wall Street Has Been Saying ?? Bullish Takeaways Mizuho keeps its fair value framework intact at $14.67 per share, which some investors read as a sign that the long term thesis on Evolus is still supported within that model. The maintained target suggests that, even after reassessing assumptions, Mizuho still sees a path that can justify this valuation level if the company executes on its plans.
Show less
Read more
Impact Snapshot
Event Time:
EOLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EOLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EOLS alerts
High impacting Evolus, Inc. news events
Weekly update
A roundup of the hottest topics
EOLS
News
- Evolus (EOLS) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "sell (d-)" to "sell (e+)".MarketBeat
- AEON Biopharma Sets Annual Shareholder Meeting [Yahoo! Finance]Yahoo! Finance
- Evolus Targets Double-Digit Growth, Full-Year Profitability at Needham Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Evolus to Report First Quarter Financial Results on May 4, 2026Business Wire
- AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 [Yahoo! Finance]Yahoo! Finance
EOLS
Earnings
- 3/3/26 - Beat
EOLS
Sec Filings
- 4/29/26 - Form DEF
- 4/29/26 - Form DEFA14A
- 4/29/26 - Form ARS
- EOLS's page on the SEC website